H. Edward Hanway

Treasurer, CEO Roundtable on Cancer
Chief Executive Officer, CIGNA

HEH.JPG H. Edward Hanway was named chairman and chief executive officer of CIGNA Corporation in 2000. Prior to that, he served the company for a year as president and chief operating officer. From 1996 to 1999 he served as president of CIGNA HealthCare, and from 1989 to 1996 as president of CIGNA International.

Mr. Hanway joined Insurance Company of North America (INA), a CIGNA predecessor company, in 1978 as assistant controller, and was appointed to management and executive roles of increasing responsibility through the merger in 1982 of INA and Connecticut General, which formed CIGNA.

Mr. Hanway serves on the board of directors of the Alliance for Health Reform and is past chairman of the Council for Affordable Quality Healthcare. He is an outspoken advocate at the national level for greater transparency in the health care quality and cost information available to consumers and a strong proponent of national quality standards for health care providers. He is recognized as a leader in the effort to improve the quality, accessibility and affordability of health care in the United States.

Through the years, Mr. Hanway has been active in a wide range of issues and initiatives associated with children's health, education and international business. He currently serves on the board of advisors of the March of Dimes Foundation, and on the board of trustees of Loyola College of Baltimore, Drexel Neumann Academy and the Eisenhower Exchange Fellowships. He also serves on the board of directors of The Philadelphia Orchestra and is a member of The Business Roundtable.

A member of the Pennsylvania and American Institutes of Certified Public Accountants, Hanway graduated from Loyola College of Baltimore (B.A., 1974) and Widener University (M.B.A., 1984).

Mr. Hanway serves as the Treasurer of the CEO Roundtable on Cancer.

 

Standard Terms of Agreement for Research Trial (START) Clauses

StartCover.png Access to standardized legal language for Key elements can increase the efficiency of contract negotiations, resulting in reduced costs and accelerating the entry of new therapies into clinical trials.

Print Page Email Page to Friend Feedback
© 2012 by Life Sciences Consortium  All rights reserved.